The role of genomics in antimicrobial discovery

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 4, 2003, Pages 749-752

  Mills, Scott D ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Antibiotic; Antimicrobial; Genomics; Target based

Indexed keywords

2 OXAZOLIDINONE DERIVATIVE; AMINO ACID TRANSFER RNA LIGASE; ANTIBIOTIC AGENT; BB 3479; HYDROXAMIC ACID DERIVATIVE; LIGASE INHIBITOR; LINEZOLID; LIPID A; LIPID X; METALLOPROTEINASE INHIBITOR; METHIONINE TRANSFER RNA LIGASE; N (1 TERT BUTYL 2 DIMETHYLAMINO 2 OXOETHYL) 2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANAMIDE; PEPTIDE DEFORMYLASE; PEPTIDE DEFORMYLASE INHIBITOR; PSEUDOMONIC ACID; SULFONAMIDE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; BACULOVIRUS EXPRESSION SYSTEM; DRUG EFFICACY; DRUG ISOLATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; ENZYME INHIBITION; ESCHERICHIA COLI; GENE SEQUENCE; HAEMOPHILUS INFLUENZAE; MICROBIAL GENETICS; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA GENITALIUM; NONHUMAN; SACCHAROMYCES CEREVISIAE; STAPHYLOCOCCUS AUREUS;

AMIDOHYDROLASES; ANTI-INFECTIVE AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENZYME INHIBITORS; GENETICS, MICROBIAL; GENOMICS; METHIONINE-TRNA LIGASE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 0037395780     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg178     Document Type: Article

References (24)

1. Diekema, D. I. & Jones, R. N. (2000). Oxazolidinones: a review. Drugs 59, 7-16.
2. Appelbaum, P. C. & Hunter, P. A. (2000). The fluoroquinolone antibacterials: past, present and future perspectives. International Journal of Antimicrobial Agents 16, 5-15.
3. Bassett, P. (2001). The antibiotic marketplace: Part I, factors influencing the market. Spectrum. Therapy and Emerging Technologies 19, 8-12; 22-24.
4. Cassell, G. H. & Mekalanos, J. (2001). Development of antimicrobial agents in the era of new and reemerging infectious diseases and increasing antibiotic resistance. Journal of the American Medical Association 285, 601-5.
5. Levy, S. B. (2001). Antibiotic resistance: consequences of inaction. Clinical Infectious Diseases 33, S124-9.
6. Fleischmann, R. D., Adams, M. D., White, O., Clayton, R. A., Kirkness, E. F., Kerlavage, A. R. et al. (1995). Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269, 496-512.
7. Fraser, C. M., Gocayne, J. D., White, O., Adams, M. D., Clayton, R. A., Fleischmann, R. D. et al. (1995). The minimal gene complement of Mycoplasma genitalium. Science 270, 397-403.
8. Koonin, E. V. (2000). How many genes can make a cell: the minimal-gene-set concept. Annual Review of Genomics and Human Genetics 1, 99-116.
9. Doolittle, R. F. (2002). Microbial genomes multiply. Nature 416, 697-700.
10. The Institute for Genomic Research's Comprehensive Microbial Resource web page, www.tigr.org (20 January 2003, date last accessed).
11. Goffeau, A., Barrell, B. G., Bussey, H., Davis, R. W., Dujon, B., Feldmann, H. et al. (1996). Life with 6000 genes. Science 274, 546, 563-7.
12. Akerley, B. J., Rubin, E. J., Novick, V. L., Amaya, K., Judson, N. & Mekalanos, J. J. (2002). A genome-scale analysis for identification of genes required for growth or survival of Haemophilus influenzae. Proceedings of the National Academy of Sciences, USA 99, 966-71.
13. Hutchison, C. A., Peterson, S. N., Gill, S. R., Cline, R. T., White, O., Fraser, C. M. et al. (1999). Global transposon mutagenesis and a minimal Mycoplasma genome. Science 286, 2165-9.
14. Arigoni, F., Talabot, F., Peitsch, M., Edgerton, M. D., Meldrum, E., Allet, E. et al. (1998). A genome-based approach for the identification of essential bacterial genes. Nature Biotechnology 16, 851-22.
15. Ji, Y., Zhang, B., Van Horn, S. F., Warren, P., Woodnut, G., Burnham, M. K. R. et al. (2001). Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science 293, 2266-9.
16. Ryan, B. M., Dougherty, T. J., Beaulieu, D., Chuang, J., Dougherty, B. A. & Barrett, J. F. (2001). Efflux in bacteria: what do we really know about it? Expert Opinion on Investigational Drugs 10, 1409-22.
17. Yuan, Z., Trias, J. & White, R. J. (2001). Deformylase as a novel antibacterial target. Drug Discovery Today 6, 954-61.
18. Clements, J. M., Beckett, R. P., Brown, A., Catlin, G., Lobell, M., Palan, S. et al. (2001). Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrobial Agents and Chemotherapy 45, 563-70.
19. Jarvest, R. L., Berge, J. M., Berry, V., Boyd, H. F., Brown, M. J., Elder, J. S. et al. (2002). Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against Gram-positive pathogens. Journal of Medicinal Chemistry 45, 1959-62.
20. Clements, J. M., Coignard, F., Johnson, I., Chandler, S., Palan, S., Waller, A. et al. (2002). Antibacterial actives and characterization of novel inhibitors of LpxC. Antimicrobial Agents and Chemotherapy 46, 1793-9.
21. Ng, W.-L., Kazmierczak, K. M., Robertson, G. T., Gilmour, R. & Winkler, M. E. (2003). Transcriptional regulation and signature patterns revealed by microarray analyses of Streptococcus pneumoniae R6 challenged with sublethal concentrations of translation inhibitors. Journal of Bacteriology 185, 359-70.
22. Lomovskaya, O., Lee, A., Hoshino, K., Ishida, H., Mistry, A., Warren, M. S. et al. (1999). Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 43, 1340-6.
23. McDevitt, D. & Rosenberg, M. (2001). Exploiting genomics to discover new antibiotics. Trends in Microbiology 9, 611-7.
24. Projan, S. J. (2002). New (and not so new) antibacterial targets - from where and when will the novel drugs come? Current Opinion in Pharmacology 2, 513-22.